Tefilli M V, Gheiler E L, Tiguert R, Grignon D J, Forman J D, Pontes J E, Wood D P
Department of Urology, Wayne State University School of Medicine and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201, USA.
Urology. 1999 May;53(5):999-1004. doi: 10.1016/s0090-4295(98)00623-2.
To evaluate the impact of urinary diversion on disease status, complications, and subsequent treatment in patients with pelvic tumor recurrence after radical cystectomy for bladder cancer.
A retrospective review of 201 consecutive cases of radical cystectomy for bladder cancer, performed at our institution between March 1991 and March 1996, identified 33 patients (16.4%) with disease recurrence in the pelvis with or without systemic metastasis. Urinary diversion in patients with tumor recurrence was an ileal conduit, continent cutaneous diversion, or orthotopic neobladder in 19, 3, and 11 patients, respectively. The mean follow-up for all patients undergoing cystectomy was 25.9 months (range 8 to 75). The mean time to diagnosis of local disease recurrence after cystectomy was 13.9 months (range 5 to 50).
In 21 (63.6%) of 33 patients, pelvic recurrence and systemic metastasis were present simultaneously. Disease recurrence was associated with poor outcome: only 8 patients (24.2%) were alive and disease free, 7 of whom had isolated local recurrence without evidence of systemic metastasis. There was no difference in overall survival or type of therapy delivered once disease recurrence was diagnosed between patients with an orthotopic neobladder and those with a cutaneous (continent or incontinent) urinary diversion. The only diversion-related complication resulting from pelvic recurrence was 1 case of tumor invasion into an orthotopic neobladder, requiring conversion to an ileal conduit.
The type of urinary diversion did not impact a patient's risk of complications, the ability to receive salvage treatment, or overall survival once pelvic recurrence was diagnosed. Patients at high risk of pelvic recurrence should not be excluded from receiving an orthotopic urinary diversion.
评估尿流改道对膀胱癌根治性膀胱切除术后盆腔肿瘤复发患者的疾病状态、并发症及后续治疗的影响。
回顾性分析1991年3月至1996年3月在我院进行的201例膀胱癌根治性膀胱切除术病例,确定33例(16.4%)盆腔有疾病复发且伴有或不伴有全身转移的患者。肿瘤复发患者的尿流改道方式分别为回肠膀胱术19例、可控性皮肤造口术3例和原位新膀胱术11例。所有接受膀胱切除术患者的平均随访时间为25.9个月(范围8至75个月)。膀胱切除术后诊断局部疾病复发的平均时间为13.9个月(范围5至50个月)。
33例患者中有21例(63.6%)同时存在盆腔复发和全身转移。疾病复发与不良预后相关:仅8例患者(24.2%)存活且无疾病,其中7例为孤立性局部复发,无全身转移证据。原位新膀胱患者与皮肤(可控或不可控)尿流改道患者在疾病复发诊断后的总生存率或治疗类型上无差异。盆腔复发导致的唯一与尿流改道相关的并发症是1例肿瘤侵犯原位新膀胱,需改为回肠膀胱术。
一旦诊断为盆腔复发,尿流改道类型不会影响患者的并发症风险、接受挽救性治疗的能力或总生存率。盆腔复发高危患者不应被排除接受原位尿流改道。